Pfizer and BioAlta are looking to push the envelope on targeted antibodies, signing an agreement that gives both companies access to the other's technology.
The companies announced Dec. 7 that they will team up to develop and commercialize BioAlta's conditionally active biologic (CAB) antibody therapeutics with Pfizer's antibody drug conjugate (ADC) payloads.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?